[go: up one dir, main page]

MX2017004559A - Receptores de celulas t. - Google Patents

Receptores de celulas t.

Info

Publication number
MX2017004559A
MX2017004559A MX2017004559A MX2017004559A MX2017004559A MX 2017004559 A MX2017004559 A MX 2017004559A MX 2017004559 A MX2017004559 A MX 2017004559A MX 2017004559 A MX2017004559 A MX 2017004559A MX 2017004559 A MX2017004559 A MX 2017004559A
Authority
MX
Mexico
Prior art keywords
tcrs
cells
nucleic acids
mage
present
Prior art date
Application number
MX2017004559A
Other languages
English (en)
Inventor
HAYES Conor
VOLKOV Arsen
Gerry Andrew
Carter Edward
BORDER Ellen
Original Assignee
Adaptimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adaptimmune Ltd filed Critical Adaptimmune Ltd
Publication of MX2017004559A publication Critical patent/MX2017004559A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a receptores de células T (TCR) los cuales unen el péptido HLA-A*02 restringido GLYDGMEHL (SEQ ID NO: 1) derivado de la proteína MAGE-A10. Los TCR de la invención demuestran excelentes perfiles de especificidad para este epitope de MAGE. También se proporcionan ácidos nucleicos que codifican los TCR; células diseñadas para presentar los TCR, células que alojan vectores de expresión que codifican los TCR y composiciones farmacéuticas que comprenden los TCR, ácidos nucleicos o células de la invención.
MX2017004559A 2014-10-08 2015-10-08 Receptores de celulas t. MX2017004559A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462061248P 2014-10-08 2014-10-08
GBGB1417803.2A GB201417803D0 (en) 2014-10-08 2014-10-08 T cell receptors
PCT/GB2015/052938 WO2016055785A1 (en) 2014-10-08 2015-10-08 T cell receptors

Publications (1)

Publication Number Publication Date
MX2017004559A true MX2017004559A (es) 2018-02-23

Family

ID=51947049

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004559A MX2017004559A (es) 2014-10-08 2015-10-08 Receptores de celulas t.

Country Status (16)

Country Link
US (1) US11203627B2 (es)
EP (1) EP3204409A1 (es)
JP (2) JP6751391B2 (es)
KR (1) KR20170092535A (es)
CN (1) CN107001443A (es)
AU (2) AU2015329783A1 (es)
BR (1) BR112017007202A2 (es)
CA (1) CA2963332A1 (es)
GB (1) GB201417803D0 (es)
IL (1) IL251524B (es)
MX (1) MX2017004559A (es)
NZ (1) NZ731571A (es)
RU (1) RU2017115932A (es)
SG (1) SG11201701983WA (es)
WO (1) WO2016055785A1 (es)
ZA (1) ZA201701823B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201417803D0 (en) * 2014-10-08 2014-11-19 Adaptimmune Ltd T cell receptors
EP3440106B1 (en) 2016-04-08 2021-09-01 Adaptimmune Limited T cell receptors
GB201616238D0 (en) * 2016-09-23 2016-11-09 Adaptimmune Ltd Modified T cells
KR20250114570A (ko) * 2017-09-22 2025-07-29 우시 바이올로직스 아일랜드 리미티드 신규한 이중특이적 폴리펩티드 복합체
CA3080546A1 (en) 2017-10-03 2019-04-11 Juno Therapeutics, Inc. Hpv-specific binding molecules
CN109879957B (zh) * 2017-12-06 2022-03-18 香雪生命科学技术（广东）有限公司 针对prame的高亲和力t细胞受体
EP3775238A1 (en) * 2018-04-05 2021-02-17 Juno Therapeutics, Inc. Methods of producing cells expressing a recombinant receptor and related compositions
GB201819540D0 (en) * 2018-11-30 2019-01-16 Adaptimmune Ltd T cell modification
EP3917969A4 (en) * 2019-01-28 2023-02-01 Wuxi Biologics Ireland Limited NEW BISPECIFIC CD3/CD20 POLYPEPTIDIC COMPLEXES
GB201904328D0 (en) * 2019-03-28 2019-05-15 Immunocore Ltd Specific binding molecules
CR20210687A (es) 2019-06-25 2022-03-03 Gilead Sciences Inc PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO
WO2021005108A1 (en) * 2019-07-09 2021-01-14 Medigene Immunotherapies Gmbh Magea10 specific t cell receptors and their use
EP4103285A2 (en) 2020-02-14 2022-12-21 Jounce Therapeutics, Inc. Antibodies and fusion proteins that bind to ccr8 and uses thereof
WO2022022696A1 (zh) * 2020-07-30 2022-02-03 香雪生命科学技术（广东）有限公司 一种识别afp的高亲和力tcr
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
AU2021410689A1 (en) * 2020-12-22 2023-07-06 Amgen Inc. Mage-b2-specific t-cell receptors
US20220389394A1 (en) 2021-05-18 2022-12-08 Gilead Sciences, Inc. METHODS OF USING FLT3L-Fc FUSION PROTEINS
TWI857377B (zh) 2021-10-28 2024-10-01 美商基利科學股份有限公司 嗒-3(2h)-酮衍生物
MX2024005066A (es) 2021-10-29 2024-05-24 Gilead Sciences Inc Compuestos de cd73.
WO2023122581A2 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
US12122764B2 (en) 2021-12-22 2024-10-22 Gilead Sciences, Inc. IKAROS zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
PE20242225A1 (es) 2022-03-17 2024-11-19 Gilead Sciences Inc Degradadores de dedos de zinc de la familia ikaros y usos de estos
AU2023256670A1 (en) 2022-04-21 2024-10-17 Gilead Sciences, Inc. Kras g12d modulating compounds
CA3260083A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. CD73 COMPOUNDS
KR20250122479A (ko) 2022-12-22 2025-08-13 길리애드 사이언시즈, 인코포레이티드 Prmt5 억제제 및 이의 용도
AU2024252725A1 (en) 2023-04-11 2025-11-06 Gilead Sciences, Inc. Kras modulating compounds
KR20250175331A (ko) 2023-04-21 2025-12-16 길리애드 사이언시즈, 인코포레이티드 Prmt5 억제제 및 이의 용도
US20250042922A1 (en) 2023-06-30 2025-02-06 Gilead Sciences, Inc. Kras modulating compounds
US20250100998A1 (en) 2023-07-26 2025-03-27 Gilead Sciences, Inc. Parp7 inhibitors
US20250066328A1 (en) 2023-07-26 2025-02-27 Gilead Sciences, Inc. Parp7 inhibitors
WO2025054530A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
WO2025054347A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Kras g12d modulating compounds
CN117003855B (zh) * 2023-09-20 2024-02-23 广州市老人院 一种t细胞受体及其应用
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0511124D0 (en) * 2005-06-01 2005-07-06 Avidex Ltd High affinity melan-a t cell receptors
JP2007032255A (ja) 2005-06-24 2007-02-08 Tokai Rika Co Ltd 車両用信号発信装置
CN101287831B (zh) * 2005-09-13 2013-05-15 国立大学法人三重大学 T细胞受体和编码该受体的核酸
GB0911566D0 (en) * 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
SG177025A1 (en) * 2010-06-21 2012-01-30 Agency Science Tech & Res Hepatitis b virus specific antibody and uses thereof
BR112013003647A2 (pt) * 2010-07-28 2017-11-07 Immunocore Ltd receptores de células t.
CA3071740C (en) * 2010-09-20 2020-09-08 Biontech Ag Antigen-specific t cell receptors and t cell epitopes
US9821073B2 (en) 2010-12-27 2017-11-21 Apo-T B.V. Polypeptide that binds aberrant cells and induces apoptosis
JP6415322B2 (ja) * 2011-09-15 2018-10-31 アメリカ合衆国 Ｈｌａ−ａ１−又はｈｌａ−ｃｗ７−拘束性ｍａｇｅを認識するｔ細胞受容体
WO2013057586A1 (en) * 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors
WO2014036562A2 (en) * 2012-08-31 2014-03-06 University Of Virginia Patent Foundation Target peptides for immunotherapy and diagnostics
US10377808B2 (en) * 2013-01-29 2019-08-13 Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) Berlin-Buch High avidity antigen recognizing constructs
GB201417803D0 (en) * 2014-10-08 2014-11-19 Adaptimmune Ltd T cell receptors
AU2017338827B2 (en) * 2016-10-03 2023-08-31 Juno Therapeutics, Inc. HPV-specific binding molecules

Also Published As

Publication number Publication date
KR20170092535A (ko) 2017-08-11
EP3204409A1 (en) 2017-08-16
JP2020127406A (ja) 2020-08-27
US20180208638A9 (en) 2018-07-26
US11203627B2 (en) 2021-12-21
AU2020203201A1 (en) 2020-06-04
WO2016055785A1 (en) 2016-04-14
AU2015329783A1 (en) 2017-05-25
JP2017533698A (ja) 2017-11-16
CA2963332A1 (en) 2016-04-14
JP6751391B2 (ja) 2020-09-02
GB201417803D0 (en) 2014-11-19
RU2017115932A3 (es) 2019-04-05
IL251524B (en) 2021-09-30
IL251524A0 (en) 2017-05-29
US20170218043A1 (en) 2017-08-03
CN107001443A (zh) 2017-08-01
ZA201701823B (en) 2019-06-26
NZ731571A (en) 2022-02-25
RU2017115932A (ru) 2018-11-12
BR112017007202A2 (pt) 2018-03-06
SG11201701983WA (en) 2017-04-27

Similar Documents

Publication Publication Date Title
MX2017004559A (es) Receptores de celulas t.
MX2018012268A (es) Receptores de celulas t.
MX2018012265A (es) Receptores de celulas t.
MX2022011309A (es) Receptores de celulas t.
NZ715038A (en) T cell receptors
PH12018502645A1 (en) Optimized mini-dystrophin genes and expression cassettes and their use
CO2017012562A2 (es) Vectores virales adenoasociados que codifican para la enzima iduronato-2-sulfatasa
CL2017001610A1 (es) Anticuerpos humanos para hemagglutinina de influenza
CL2017001883A1 (es) Compuestos antisenescentes y usos de los mismos
EA201991431A1 (ru) УСИЛЕННЫЙ ОПОСРЕДОВАННЫЙ ТРАНСПОЗОНАМИ СЕМЕЙСТВА hAT ПЕРЕНОС ГЕНОВ И АССОЦИИРОВАННЫЕ КОМПОЗИЦИИ, СИСТЕМЫ И СПОСОБЫ
CU20190006A7 (es) Composiciones para inhibir masp-3
CY1124425T1 (el) Συνθεσεις οι οποιες περιλαμβανουν συζευγματα φαρμακου αντισωματος-δουοκαρμυκινης
BR112016026842A2 (pt) preparação compreendendo fator viii e peptídeos de fator de von willebrand
ES2722773T3 (es) Polipéptidos de fHbp meningocócicos modificados
CY1122644T1 (el) Πρωτεϊνες συντηξης tatk-cdkl5, συνθεσεις, φαρμακοτεχνικες μορφες και η χρηση αυτων
WO2015145449A3 (en) T-cell receptor cdr3 peptides and antibodies
WO2015107363A3 (en) Mycobacterial antigen composition
BR112016019390A2 (pt) proteínas de fusão uti
CO2019004193A2 (es) Vacuna de adn tolerogénica
MX2018003445A (es) Expresion de proteinas que contienen fc.
MX380003B (es) Péptidos topk y vacunas que incluyen los mismos.
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
UA113413C2 (uk) Пептид mphosph1 та вакцина, що його містить
BR112019007343A2 (pt) sequência de nucleotídeos expressando uma proteína de ancoragem de exossomo para uso como vacina
BR112015010625A2 (pt) Peptídeos